NLRP3 inflammasome in metabolic syndrome
Braz. J. Pharm. Sci. (Online)
;
56: e18968, 2020.
Artículo
en Inglés
| LILACS
| ID: biblio-1249173
ABSTRACT
Metabolic syndrome (MS) is a serious health problem worldwide; it is characterized by a group of metabolic disorders, including central obesity, insulin resistance/type 2 diabetes, hyperlipidemia with accelerated atherosclerosis, hypertension, non-alcoholic fatty liver disease, and elevated uric acid with increased risk of gout. The incidence of MS has increased considerably in recent decades and has attracted considerable attention. A number of clinical and translational laboratory studies have implicated the activation of nucleotide-binding domain and leucine-rich repeat protein 3 (NLRP3) inflammasome in the development of MS, therefore establishing a strong link between chronic inflammation and metabolic diseases. This paper aims to review new developments on NLRP3 inflammasome in MS for better understanding of chronic inflammation in metabolic diseases. We will also provide new insights into using NLRP3 inflammasome as an innovative therapeutic target.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Inflamasomas
/
Enfermedades Metabólicas
Idioma:
Inglés
Revista:
Braz. J. Pharm. Sci. (Online)
Asunto de la revista:
Farmacologia
/
Teraputica
/
Toxicologia
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
China
Institución/País de afiliación:
Central South University/CN
Similares
MEDLINE
...
LILACS
LIS